Lacosamide

Emilio Perucca, Uma Yasothan, Gilbert Clincke, Peter Kirkpatrick

Research output: Contribution to journalArticlepeer-review

Abstract

In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.

Original languageEnglish
Pages (from-to)973-974
Number of pages2
JournalNature Reviews Drug Discovery
Volume7
Issue number12
DOIs
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint

Dive into the research topics of 'Lacosamide'. Together they form a unique fingerprint.

Cite this